President Joe Biden and Sen. Bernie Sanders in a Tuesday op-ed in USA Today called on Novo Nordisk and Eli Lilly to “stop ripping off Americans” with “unconscionably high prices” for their GLP-1 medicines. https://hubs.li/Q02Ff_mJ0
BioSpace’s Post
More Relevant Posts
-
https://lnkd.in/eSSBt-RR Takeaway: The Federal Trade Commission said it is examining the role that drug wholesalers and companies that purchase medicines for U.S. health-care providers play in shortages of generic drugs, which account for the majority of Americans’ prescriptions. The move follows an unprecedented shortfall of crucial medicine ranging from injectable cancer therapies to generics, or cheaper versions of brand-name medicines, over the last year, which has forced hospitals and patients to ration drugs. Problems from manufacturing quality control to demand surges can drive supply issues.
Biden administration examining role of supply chain middlemen in generic drug shortages
cnbc.com
To view or add a comment, sign in
-
Paediatric and Emergency Doctor | Podcast host at Revolving Door Syndrome | Honorary Lecturer, School of Medicine
Todd Stephenson may not be in the executive but you cannot exclude the potential influence this may allow the pharmaceutical industry over NZ's drug buying agency PHARMAC. Stephenson was imported straight from the pharmaceutical industry into a role as Parliamentary Undersecretary to the Associate Minister of Health (PHARMAC) while also investing in the pharmaceutical industry. In what world is this not a conflict of interest? What is news to me is that MPs do not have to declare in full, the value of all pecuniary interests. It brings into question the strength of our democracy as we wonder who or what members are truly there to represent. It brings into question the idea of one person, one vote, when clearly those with money have more influence and therefore power over our government. Paying pharmaceutical companies for their products is necessary to provide modern healthcare. But my sympathy is limited when I see the large amount of profits made from our sickness system. I feel for our patients but my question is why must these life-saving drugs carry such a high price tag? What would really reduce our healthcare expenditure is if we created an environment that kept people healthy, prevented diabetes, hypertension and cancers while also running a functioning health system that picked up cancers early. Then maybe we would have more money to treat unpreventable rare diseases. So lets see what happens with PHARMAC. There's an argument for a whole of government approach that allows people to access treatments to stay well enough to continue contributing to society. There really are benefits in staying engaged in communities and occupied. All of our MPs should declare all pecuniary interests. Or we will never know if they're in it for corporations or for us. #medicine #pharmaceuticals #pharmacy #doctor #healthcare #health #publichealth #pharmac #aotearoa #newzealand #prevention #screening #earlyintervention #democracy
MP advising minister on Pharmac has investments in pharmaceutical companies
nzherald.co.nz
To view or add a comment, sign in
-
Approximately 90% of prescription drugs used today are generics, which has saved American taxpayers nearly $3 trillion over the past decade. Still, factors such as unsustainably low prices, manufacturing complexity, geographic concentration, and quality issues weaken the medicines supply chain, putting patient access to quality medications at risk. The 1984 Drug Price Competition and Patient Term Restoration Act – also known as the Hatch-Waxman Act – created a pathway for more affordable generic medicines to enter the market and incentivized the development of new, innovative medicines for patients. Today, the same spirit of collaboration and urgency that guided Hatch-Waxman can support meaningful improvements to patient access. Check out USP’s policy paper titled ‘Identifying and addressing vulnerabilities in the upstream medicines supply chain to build resilience and reduce drug shortages’ to learn more about how collaboration from policymakers, drug purchasers and other industry stakeholders can help address supply chain vulnerabilities and increase patient access to quality medications. ⤵️
To view or add a comment, sign in
-
Pharmaceutical leaders #EliLilly and #NovoNordisk are addressing the rise of compounding pharmacies producing lower-cost versions of obesity medications like #Zepbound and #Wegovy. Compounders claim to be meeting patient needs during drug shortages, but there are concerns over regulatory compliance and patient safety. Why it matters: This development is testing the boundaries of FDA regulations surrounding drug compounding, raising questions about the long-term impact on healthcare access and safety standards. Angela Fitch MD, FACP, FOMA, Dipl. ABOM, former president of the Obesity Medicine Association, commented: "We've never done this before in healthcare. This is like a gigantic, huge scientific experiment." As the conversation evolves, maintaining patient safety and access to care remain top priorities for all involved. What are your thoughts on the balance between access and safety in this debate? https://ow.ly/YxPO50Tkim9
Weight-loss drug boom sparks battle over pharmacy copycats
axios.com
To view or add a comment, sign in
-
Here is the English version of the interview in El País. Once more, thank you Oriol Güell for the discussion during the Annual Conferences of Medicines for Europe. My goal is trying to showcast that generic medicines need price review mechanisms to remain profitable (and avaialble on the market) and that Europe should invvest and promote the existing pharma industry as well as attract new players to our continent. Generic medicines are key for the European Healthcare systems, so they deserve special measures if we want to strengthen European Health autonomy. #generic drugs #europe #medicinesforeurope
Elisabeth Stampa: ‘Many drugs that used to be produced in Europe are now manufactured in Asia. This makes us vulnerable to shortages’
english.elpais.com
To view or add a comment, sign in
-
The rising popularity of compounded medications is a concerning trend. As awareness grows and efforts to regulate these compounders intensify, it's crucial to recognize that the high demand for anti-obesity drugs, coupled with limited access due to their high cost, is likely driving the production of these medications. Doctors face the challenging task of advocating for their patients and navigating the complexities of insurance coverage for these essential treatments. With approximately 9 million individuals living with obesity in Canada, how can we bridge this gap in access and support. #Healthcare #Obesity #CompoundedMedications #PatientAdvocacy #AccessToCare
Pharmaceutical leaders #EliLilly and #NovoNordisk are addressing the rise of compounding pharmacies producing lower-cost versions of obesity medications like #Zepbound and #Wegovy. Compounders claim to be meeting patient needs during drug shortages, but there are concerns over regulatory compliance and patient safety. Why it matters: This development is testing the boundaries of FDA regulations surrounding drug compounding, raising questions about the long-term impact on healthcare access and safety standards. Angela Fitch MD, FACP, FOMA, Dipl. ABOM, former president of the Obesity Medicine Association, commented: "We've never done this before in healthcare. This is like a gigantic, huge scientific experiment." As the conversation evolves, maintaining patient safety and access to care remain top priorities for all involved. What are your thoughts on the balance between access and safety in this debate? https://ow.ly/YxPO50Tkim9
Weight-loss drug boom sparks battle over pharmacy copycats
axios.com
To view or add a comment, sign in
-
Cause and effect. These unregulated drug compounders won't exist if they are not commercially viable. If Eli Lilly and Novo Nordisk would stop limiting their production and make them accessible to the rest of the millions who need them, those who could neither afford them nor find them, i am sure most people would choose regulated products over unregulated ones for safety. I am also sure, they can still profit from the drug since these are regular, maintenance medications that a single patient out of millions would probably be using long term, if not for the rest of their lives. The fact that compounders exist to fill in the gaps in the market means that it is relatively easy to produce these medications. So it is beyond me why a multi-billion, multinational pharmaceutical company are struggling to keep up with demand.
Pharmaceutical leaders #EliLilly and #NovoNordisk are addressing the rise of compounding pharmacies producing lower-cost versions of obesity medications like #Zepbound and #Wegovy. Compounders claim to be meeting patient needs during drug shortages, but there are concerns over regulatory compliance and patient safety. Why it matters: This development is testing the boundaries of FDA regulations surrounding drug compounding, raising questions about the long-term impact on healthcare access and safety standards. Angela Fitch MD, FACP, FOMA, Dipl. ABOM, former president of the Obesity Medicine Association, commented: "We've never done this before in healthcare. This is like a gigantic, huge scientific experiment." As the conversation evolves, maintaining patient safety and access to care remain top priorities for all involved. What are your thoughts on the balance between access and safety in this debate? https://ow.ly/YxPO50Tkim9
Weight-loss drug boom sparks battle over pharmacy copycats
axios.com
To view or add a comment, sign in
-
Policy, Innovation and policy innovation. Digital health; impact investing. Yoga instructor; dog wrangler.
Well argued. The extension of bulk savings nationally presumes a well functioning infrastructure that does not exist and isn’t easily achievable. It would also be an easy target if it did exist. These are distractions to the very real equity issues that need to be solved.
Ottawa says single payer pharmacare is required to control the cost of new drugs. Read my latest comment to find out why this is bogus. #pharmacare #cdnpoli
Opinion: Controlling drug costs doesn't require pharmacare
financialpost.com
To view or add a comment, sign in
118,144 followers
Drug Discovery | Innovation | Business Development & Strategy | Entrepreneurship
3moI'd advise everyone to check out No Patient Left Behind and the concept of "investing" in innovation as a society. Price controls would be very dangerous for the future of drug discovery. It could stifle innovation and slow the progress of medical advancements. Unfortunately, it is very complicated but everyone should understand the investment we need to make as society to ensure we continue to come up with life changing and life saving drugs. This does come with some higher initial drug prices. We are not paying for just the drug you see but all the innovation that had to occur to get there which does include A LOT of failures in drug discovery which are very expensive and future innovation to make the next amazing drug which has a lot of failures and is very expensive. Just think about what this may do long term for drug innovation. I can promise price controls will not have the long term result you are hoping for.